siplizumab
mAbexperimental
Siplizumab (MEDI-507) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and has been tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease. — Wikipedia
Clinical trial activity
27 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
15
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 1997 (NCT00807794)
Timeline
Indications
Studied for
- Amyotrophic Lateral Sclerosis · Phase 1
- Anemia, Sickle Cell · Phase 1/Phase 2
- Autoimmune Diseases · Phase 1
- Chimera · Phase 1/Phase 2
- Cholangitis, Sclerosing · Phase 1
- Diabetes Mellitus, Type 1 · Phase 2
- End Stage Liver Disease · Phase 1
- Graft vs Host Disease · Phase 1
- Hepatitis, Autoimmune · Phase 1
- Hidradenitis Suppurativa · Early Phase 1
- Immunosuppression Therapy · Early Phase 1
- Kidney Diseases · Phase 1
- Kidney Failure, Chronic · Phase 2
- Kidney Transplantation · Phase 2
- Leukemia · Phase 2
- Liver Cirrhosis · Phase 1
- Liver Transplantation · Phase 2
- Lymphoma · Phase 2
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Lymphoproliferative Disorders · Phase 1
- Multiple Myeloma · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 1
- Psoriasis · Phase 2
- Renal Insufficiency · Phase 1/Phase 2
Mechanism of action
- T-cell surface antigen CD2INHIBITOR
CD2 inhibitor
The antibody tumor-killing action is a FcR¿-dependent mechanism presumably mediated by effector cells, including monocytes and granulocytes that express FcR¿III.
- Complement receptor type 2INHIBITOR
CR2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSiplizumab ↗
- ChEMBLCHEMBL2109345 ↗
- ChEMBLCHEMBL2108742 ↗
Also known as
- allomune
- medi507
- medi-507
- medi-507
- medi-507
- siplizumab
- siplizumab
- siplizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06972069 | Early Phase 1 (Phase 1) | May 31, 2025 | Eledon Pharmaceuticals, Harvard University, ITB-Med LLC |
| NCT06326476 | Early Phase 1 (Phase 1) | Jan 31, 2025 | ITB-Med LLC, University of Alabama, Birmingham |
| NCT06455280 | Phase 1 | Sep 11, 2024 | Columbia University, ITB-Med LLC |
| NCT06453668 | Phase 1 | Apr 16, 2024 | ITB-Med LLC |
| NCT05900401 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2023 | Harvard University, ITB-Med LLC, Ossium Health, Inc. |
| NCT06078696 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2023 | Columbia University, ITB-Med LLC |
| NCT05669001 | Phase 2 | Apr 30, 2023 | ITB-Med LLC |
| NCT06025110 | Phase 2 | Jan 23, 2023 | ITB-Med LLC |
| NCT05574335 | Phase 1/Phase 2 (Phase 2) | Dec 27, 2022 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco |
| NCT06019507 | Phase 2 | Jun 29, 2022 | ITB-Med LLC |
| NCT04803058 | Phase 2 | Jul 31, 2021 | ITB-Med LLC |
| NCT04803006 | Phase 2 | Jul 31, 2021 | ITB-Med LLC |
| NCT06365437 | Phase 2 | Jun 6, 2021 | ITB-Med LLC |
| NCT04311632 | Phase 2 | Jun 30, 2020 | ITB-Med LLC |
| NCT01780454 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | Harvard University |
| NCT01445535 | Phase 1 | Jan 12, 2009 | National Cancer Institute (NCI) |
| NCT00801632 | Phase 2 | Dec 1, 2008 | Harvard University, Immune Tolerance Network, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00105313 | Phase 1 | Feb 1, 2005 | MedImmune |
| NCT00123942 | Phase 1 | Apr 1, 2004 | MedImmune, National Cancer Institute (NCI) |
| NCT00063817 | Phase 1 | Jun 1, 2003 | Harvard University, Immune Tolerance Network, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 20 of 27 trials
Page 1 / 2
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ITB-Med LLC | For profit | 13 | 8 | 2 | 2020 |
| MedImmune | For profit | 8 | 8 | 2 | 1997 |
| Harvard University | Academic/Hospital | 6 | 4 | 2 | 2002 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 2 | 2003 |
| Columbia University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Immune Tolerance Network | Academic/Hospital | 2 | 0 | 2 | 2003 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2004 |
| Eledon Pharmaceuticals | For profit | 1 | 0 | 1 | 2025 |
| Ossium Health, Inc. | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2022 |
11 organizations
Page 1 / 1